{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/trichomoniasis/management/management/","result":{"pageContext":{"chapter":{"id":"1c2af37c-700d-5c7c-95ea-049cde93a7e1","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 3c8a357e-6cfa-457c-a895-c109078fa498 --><h2>Scenario: Management of trichomoniasis</h2><!-- end field 3c8a357e-6cfa-457c-a895-c109078fa498 -->","summary":"Covers the management of confirmed trichomoniasis in men and women, and the management of sexual partners.","htmlStringContent":"<!-- begin item 3a844785-ed9e-4a8c-a3e1-f08d929dd007 --><!-- begin field a1ad53e3-f1f3-4f1d-b60f-acbd0086569d --><p>From age 13 years onwards.</p><!-- end field a1ad53e3-f1f3-4f1d-b60f-acbd0086569d --><!-- end item 3a844785-ed9e-4a8c-a3e1-f08d929dd007 -->","topic":{"id":"3fa4323b-9014-5631-9410-a93ec7d2d0ac","topicId":"97ea63d1-8933-4fee-b1dd-7c6ac3ea2ab7","topicName":"Trichomoniasis","slug":"trichomoniasis","lastRevised":"Last revised in May 2020","chapters":[{"id":"e42d9436-b807-5262-a262-948244b520b5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2b56e4dc-02e3-599e-a6bf-1a5413d868f0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"46f9586c-8974-558f-8ac1-6244bfd1883b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"65ddd7d3-15b0-53be-866f-5610e15e070d","slug":"changes","fullItemName":"Changes"},{"id":"c386cd94-aafd-5fe3-8a55-e502f9f681d1","slug":"update","fullItemName":"Update"}]},{"id":"a7c1505d-66b8-52d6-9b36-239f3eadfed0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c0dae047-42fb-5e25-9862-8967f319e9ee","slug":"goals","fullItemName":"Goals"},{"id":"a4744067-6bed-5f73-8911-66c7ff78570c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"89cbccbf-01cf-5343-bfb7-bad7760a2ded","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8b5c3a47-9564-552f-83c2-64f8926bec29","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6cd42b4c-a956-560f-9c6c-a0e3521bbace","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9f22fed3-714e-5abe-9a52-34870887e267","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2ebe6cd7-4b6e-5541-9699-5f4e0af542fe","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b4bf3870-e41e-51aa-8ea8-ce962d1735b8","slug":"definition","fullItemName":"Definition"},{"id":"9aec8640-ee39-5d2f-97df-a62f06464af5","slug":"prevalence","fullItemName":"Prevalence"},{"id":"82e41ac8-9c05-5599-bdc6-d1ea0a1ecf7a","slug":"complications","fullItemName":"Complications"}]},{"id":"d1509154-ef5a-52ae-9c75-a9b6bf3bd4bf","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7159a76b-b760-5ee5-8e00-afc991a5ecb9","slug":"diagnosis-women","fullItemName":"Diagnosis - women"},{"id":"159b50a4-88fe-5cf2-9af2-43893eeeec84","slug":"diagnosis-men","fullItemName":"Diagnosis - men"}]},{"id":"004f5906-27c9-56f0-a599-802d0bdffa7c","fullItemName":"Management","slug":"management","subChapters":[{"id":"1c2af37c-700d-5c7c-95ea-049cde93a7e1","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"b06121d3-a41a-5e65-a720-76900da7e5e7","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4c83875e-ed21-58f7-99f4-4a509deb53b5","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"cdff86f4-ac12-56d7-b196-c5f9af1eb880","slug":"tinidazole","fullItemName":"Tinidazole"}]},{"id":"9e19b288-e085-5577-8ad2-b0a504a27f7f","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7ab5ef58-ff30-5498-8faa-115c4d60dd3f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"11960892-2762-52d0-8fac-3c436e4d4738","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a0cf5333-25ca-5bf8-9b3b-547067cd8d5f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d9ecf639-6f52-5f87-85be-f921ce43f237","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"24dfa3bf-b2cc-5ace-9f72-a47e822dd30a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7c7dfdd9-03c3-520f-a183-13ce32d19151","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c998f4ca-7088-5e78-95d0-67151407d497","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"004f5906-27c9-56f0-a599-802d0bdffa7c","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"fc5706aa-adcd-5800-a256-71848e3dd38a","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 7ec97139-f4a6-438a-ba72-1ed14b30558f --><h3>How should I manage a person with confirmed trichomoniasis?</h3><!-- end field 7ec97139-f4a6-438a-ba72-1ed14b30558f -->","summary":null,"htmlStringContent":"<!-- begin item 0dbf1ed0-8120-4013-a3a2-bd32570bcaf6 --><!-- begin field ed508703-9892-4468-b716-212eb9bf9e81 --><p><strong>Ideally, treatment of confirmed trichomoniasis should be provided by a genito-urinary medicine (GUM) clinic or other local specialist sexual health service. </strong><strong>If this is declined or not possible, the person should be managed in primary care.</strong></p><p><strong>If a sexually transmitted infection (STI) is suspected or diagnosed in a child or young person, the healthcare professional should have a low threshold for discussing with a GUM specialist or paediatrician, and local child safeguarding procedures should be followed. Further information is available in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/child-maltreatment-recognition-management/\">Child maltreatment - recognition and management</a>.</strong></p><ul><li><strong>Offer written information </strong><strong>on trichomoniasis as an STI, </strong>including information on possible complications and measures to reduce the risk of further STIs. Patient information is available from:<ul><li>The Family Planning Association (FPA): <a data-hyperlink-id=\"07ceea96-92cf-42c0-91d3-a98c014d3339\" href=\"http://www.fpa.org.uk/sites/default/files/trichomonas-vaginalis-information-and-advice.pdf\">Trichomonas vaginalis. Looking after your sexual health</a>.</li><li>The NHS website: <a data-hyperlink-id=\"0b732f9e-e59b-4afa-b1f8-ab0e01330c1e\" href=\"https://www.nhs.uk/conditions/trichomoniasis/\">Trichomoniasis</a>.</li></ul></li><li><strong>Treat the infection.</strong><ul><li>For men and women (not pregnant or breastfeeding):<ul><li>Prescribe oral metronidazole 400–500 mg twice a day for 5–7 days, <em>or </em>metronidazole 2 g as a single oral dose, <em>or</em> tinidazole 2 g as a single oral dose.</li><li>Seek advice from a GUM specialist if the person has a confirmed metronidazole and tinidazole allergy.</li></ul></li><li>For breastfeeding women and symptomatic pregnant women:<ul><li>Prescribe oral metronidazole 400–500 mg twice a day for 5–7 days.</li><li>Where possible, inform other healthcare professionals involved in the woman's care (such as the woman's midwife and obstetrician) of the diagnosis and treatment.</li><li>Seek specialist advice from a GUM specialist if the woman is unable or unwilling to take metronidazole.</li><li>High-dose metronidazole (2 g single dose) and tinidazole are not recommended during pregnancy and breastfeeding.</li></ul></li><li>For asymptomatic pregnant women: <ul><li>Seek specialist advice from a GUM specialist.</li></ul></li><li>For people with HIV:<ul><li>Prescribe oral metronidazole 500 mg twice a day for 7 days.</li><li>Seek advice from a GUM specialist if the person has a confirmed metronidazole allergy.</li></ul></li><li><strong>Treat current partner(s) simultaneously, and also treat any partner(s) from within the 4-week period prior to presentation.</strong></li></ul></li><li><strong>Offer screening for other STIs (if not already done).</strong> See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/trichomoniasis/diagnosis/diagnosis-women/\">Diagnosis - women</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/trichomoniasis/diagnosis/diagnosis-men/\">Diagnosis - men</a> for more information.<ul><li>Also screen the person's current partner(s) and partner(s) from within the 4-week period prior to presentation. </li></ul></li><li><strong>Arrange follow up </strong><strong>after treatment to:</strong><ul><li>Review the person for persistent symptoms, which may indicate <a class=\"topic-reference internal-reference\" href=\"/topics/trichomoniasis/management/management/#treatment-failure\">treatment failure</a>.</li><li>Confirm that contact tracing has been carried out.</li><li>Discuss the results of the STI screen.</li></ul></li><li><strong>Advise sexual abstinence </strong>for at least one week and until the person and partner(s) have completed treatment and follow up.</li><li><strong>Do not routinely test to confirm cure.</strong></li></ul><!-- end field ed508703-9892-4468-b716-212eb9bf9e81 --><!-- end item 0dbf1ed0-8120-4013-a3a2-bd32570bcaf6 -->","subChapters":[{"id":"9685d8d1-382c-55a2-b126-560f25a68ccc","slug":"basis-for-recommendation-f9a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b7596f84-10f3-4d13-b0b5-870d8cd03c84 --><h4>Basis for recommendation</h4><!-- end field b7596f84-10f3-4d13-b0b5-870d8cd03c84 -->","summary":null,"htmlStringContent":"<!-- begin item f9af93ed-c2ce-4b17-b531-324963e31c83 --><!-- begin field 6e7855c8-654e-4389-b990-e9731391098d --><p>These recommendations are largely based on the Royal College of General Practitioners (RCGP) and British Association of Sexual Health and HIV (BASHH) guideline <em>Sexually Transmitted infections in Primary Care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Lazaro, 2013</a>], the BASHH<em> United Kingdom National Guidelines on the Management of Trichomoniasis vaginalis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2014</a>], the National Institute for Health and Care Excellence (NICE) and Public Health England (PHE) publication <em>Summary of antimicrobial prescribing guidance – managing common infections (September 2019) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">NICE and PHE, 2019</a>], and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Joint Formulary Committee, 2019</a>].</p><h5>Referral to a genito-urinary medicine (GUM) clinic or other local specialist sexual health service</h5><ul><li>Expert opinion in the RCGP/BASHH guideline is that people with suspected trichomoniasis should be referred to a GUM clinic as they are better placed to consider the validity of the test result, screen for other sexually transmitted infections (STIs), and perform contact tracing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Lazaro, 2013</a>].</li></ul><h5>Managing a child or young person</h5><ul><li>This recommendation is based on the RCGP/BASHH guideline<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Lazaro, 2013</a>].</li></ul><h5>Treating men and women (not pregnant or breastfeeding) </h5><ul><li>Metronidazole is licensed for the treatment of urogenital trichomoniasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Joint Formulary Committee, 2019</a>].<ul><li>Experts recommend a dosage of 400–500 mg twice a day for 5–7 days <em>or</em>  2 g as a single dose for the treatment of trichomoniasis in men and women<strong> </strong>who are not pregnant or breastfeeding<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Lazaro, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">NICE and PHE, 2019</a>].</li><li>However, evidence from a meta-analysis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Howe, 2017</a>] and an open-label, randomized controlled trial (RCT) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Kissinger 2018</a>] suggest that there is higher treatment failure for the single-dose metronidazole treatment regimen compared with the 7-day regimen.</li></ul></li><li>Tinidazole is licensed for the treatment of urogenital trichomoniasis and is recommended as an alternative to metronidazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Lazaro, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2014</a>]. It has similar activity to metronidazole (although a longer duration of action) but is more expensive [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Joint Formulary Committee, 2019</a>]. </li></ul><p><strong>Treating </strong><strong><strong>b</strong>reastfeeding women and symptomatic pregnant women</strong></p><ul><li>This recommendation is based on the BASHH guideline and NICE/PHE guideline<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">NICE and PHE, 2019</a>].</li><li>The recommendation to inform other healthcare professionals (for example the midwife and obstetrician) is based on what CKS considers to be good medical practice.</li><li>Information regarding the safety of metronidazole in pregnancy and breastfeeding is summarized in the section on <a class=\"topic-reference internal-reference\" href=\"/topics/trichomoniasis/prescribing-information/metronidazole/#pregnancy-breastfeeding\">Pregnancy and breastfeeding</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/trichomoniasis/prescribing-information/metronidazole/#pregnancy-breastfeeding\">Prescribing information</a>.</li></ul><p><strong>Treating asymptomatic pregnant women</strong></p><ul><li>CKS recommends seeking specialist advice in asymptomatic pregnant women due to the lack of consensus regarding optimal treatment of this group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Gulmezoglu and Azhar, 2011</a>].</li></ul><p><strong>Treating people with HIV</strong></p><ul><li>This recommendation is based on the BASHH guideline<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2014</a>].<ul><li>An RCT identified by BASHH demonstrated that 2 g single-dose metronidazole was not as effective as metronidazole 500 mg twice daily for 5–7 days in people with HIV [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Kissinger et al, 2010</a>].</li></ul></li></ul><h5>When to seek specialist advice</h5><ul><li>The recommendation to seek advice from a GUM specialist for people with metronidazole and tinidazole allergy is based on the RCGP/BASHH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Lazaro, 2013</a>] and the BASHH guideline<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2014</a>]. </li></ul><p><strong>Treating partners</strong></p><ul><li>This recommendation is based on the RCGP/BASHH guideline and the BASHH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Lazaro, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2014</a>].</li></ul><p><strong>Offering STI screening</strong></p><ul><li>Concurrent STI screening is recommended in the RCGP/BASHH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Lazaro, 2013</a>], the BASHH guideline on the Management of <em>T. vaginalis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2014</a>], and the BASHH <em>CEG guidance on tests for Sexually Transmitted Infections</em> (published by the BASHH Clinical Effectiveness Group) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2015</a>].</li></ul><p><strong>Advice regarding sexual abstinence</strong></p><ul><li><p>This recommendation is based on the BASHH guideline<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2014</a>].</p></li></ul><p><strong>Follow-up arrangements</strong></p><ul><li><p>This recommendation is based on the BASHH guideline<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2014</a>].</p></li></ul><!-- end field 6e7855c8-654e-4389-b990-e9731391098d --><!-- end item f9af93ed-c2ce-4b17-b531-324963e31c83 -->","subChapters":[]}]},{"id":"10926cbe-a86c-5fc5-84c7-63a89733ed23","slug":"treatment-failure","fullItemName":"Treatment failure","depth":3,"htmlHeader":"<!-- begin field 4d3e5ac4-1c8a-4dda-9158-6c616001d4fa --><h3>How should I manage treatment failure?</h3><!-- end field 4d3e5ac4-1c8a-4dda-9158-6c616001d4fa -->","summary":null,"htmlStringContent":"<!-- begin item 62ce77cc-c9d9-42ec-a383-c905abc6e3c7 --><!-- begin field 42e6875d-be8d-4cdf-9b6f-b95032cdb089 --><ul><li>​​​​​​<strong>If symptoms persist or recur after the <a class=\"topic-reference internal-reference\" href=\"/topics/trichomoniasis/management/management/#management\">first-line treatment</a> is completed, </strong>the person should ideally be treated by a genito-urinary medicine (GUM) clinic or other local specialist sexual health service. If this is declined or not possible:<ul><li><strong>Check adherence to the first-line treatment</strong>.</li><li><strong>Exclude the possibility of reinfection. </strong><ul><li>Check that current partner(s) have been treated appropriately and simultaneously.</li></ul></li><li><strong>Reconsider the diagnosis. </strong><ul><li>Ensure that other causes of symptoms have been excluded. For more information in women, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/vaginal-discharge/\">Vaginal discharge</a>. For more information in men, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/urethritis-male/\">Urethritis - male</a>.</li><li>Offer repeat testing. For more information on the tests, see the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/trichomoniasis/diagnosis/diagnosis-women/\">Diagnosis - women</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/trichomoniasis/diagnosis/diagnosis-men/\">Diagnosis - men</a>. Leave 48 hours after the end of initial treatment before re-testing.</li></ul></li><li><strong>Manage the infection.</strong><ul><li>For men and women (not pregnant or breastfeeding), repeat the 7-day course of metronidazole treatment (400–500 mg twice a day).</li><li>For pregnant or breastfeeding women, discuss with a GUM specialist or the woman's obstetrician before prescribing any further treatment.</li></ul></li><li><strong>Seek advice from a GUM specialist:</strong><ul><li>If the second-line treatment regimen fails.</li><li>For people with failed first-line single-dose treatment.</li></ul></li></ul></li></ul><!-- end field 42e6875d-be8d-4cdf-9b6f-b95032cdb089 --><!-- end item 62ce77cc-c9d9-42ec-a383-c905abc6e3c7 -->","subChapters":[{"id":"dc427d7f-4d1c-5d6f-9da4-1ac5704d7df5","slug":"basis-for-recommendation-3f5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c6b03df8-1895-4337-97e1-c0e4c1d1af37 --><h4>Basis for recommendation</h4><!-- end field c6b03df8-1895-4337-97e1-c0e4c1d1af37 -->","summary":null,"htmlStringContent":"<!-- begin item 3f57012f-ae52-4712-ac94-d2b0dd8a4b06 --><!-- begin field a2b5435f-549b-40ec-b920-7495027f3752 --><p>These recommendations are largely based on the British Association of Sexual Health and HIV<em>(BASHH) United Kingdom National Guidelines on the Management of Trichomoniasis vaginalis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2014</a>].</p><h5>Managing people who do not respond to the first-line treatment</h5><ul><li>Evidence identified by BASHH showed that 40% of non-responders to metronidazole 400–500 mg twice daily for 5–7 days responded to a repeat course.</li><li>A 7-day (rather than 5-day) course is specified as second-line treatment.</li></ul><h5>When to seek specialist advice</h5><ul><li>For people who do not respond to the second-line treatment, BASHH recommends higher dose treatment (metronidazole or tinidazole 2 g daily for 5–7 days, or metronidazole 800 mg three times daily for 7 days) based on evidence that 70% of people responded to higher doses of metronidazole.</li><li>However, CKS recommends seeking specialist advice as these are off-label doses.</li></ul><!-- end field a2b5435f-549b-40ec-b920-7495027f3752 --><!-- end item 3f57012f-ae52-4712-ac94-d2b0dd8a4b06 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}